Based on previously reported results [16,38,39], anti-TNFα, anti-IL-1, or anti-RANKL therapy was begun on day 4 after initial onset of arthritis, when paw swelling was at or near its peak in both CIA and AIA rats (Figure 1a). The gene discussed is IL1B; the disease is arthritic joint disease.